Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0028 | 0.452342487884 | 0.619 | 0.655 | 0.6087 | 177152 | 0.62246016 | CS |
4 | -0.0632 | -9.22627737226 | 0.685 | 0.7 | 0.6087 | 138368 | 0.64732815 | CS |
12 | -0.1102 | -15.0546448087 | 0.732 | 0.78 | 0.6087 | 164381 | 0.70427528 | CS |
26 | -0.5382 | -46.3965517241 | 1.16 | 1.56 | 0.6087 | 195077 | 0.84736319 | CS |
52 | -0.4882 | -43.981981982 | 1.11 | 1.56 | 0.6087 | 162699 | 0.93455127 | CS |
156 | -14.5982 | -95.914586071 | 15.22 | 15.22 | 0.6087 | 202651 | 2.48238711 | CS |
260 | -21.3682 | -97.1723510687 | 21.99 | 43.07 | 0.6087 | 192617 | 6.85924742 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.